Ewing Sarcoma Treatment
Ribociclib combined with everolimus elicits tumor responses in patients with advanced dedifferentiated liposarcoma.
A phase 2 trial (SAR-096, NCT03114527) evaluated ribociclib plus everolimus in patients with advanced dedifferentiated liposarcoma (DDLPS). The combination produced disease stabilization and two confirmed partial responses among 21 enrolled patients, with a tolerable safety profile. Biomarker analyses are planned to identify predictive markers for response.
This finding provides evidence that dual CDK4 and mTOR inhibition can produce objective responses in a sarcoma subtype that has shown limited activity with CDK4 inhibitors alone, offering a potential new therapeutic option for DDLPS patients.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine—A Systematic Review
- Leiomyosarcoma
- Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study
- Lineage-defined leiomyosarcoma subtypes emerge years before diagnosis and determine patient survival
- Immunotherapy-based salvage therapy in advanced soft tissue sarcoma after first-line chemotherapy: a retrospective single-center analysis with emphasis on undifferentiated pleomorphic sarcoma